BRAINSTORM CELL THERAPEUTICS INC. (BCLI) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US10501E2019
BRAINSTORM CELL THERAPEUTICS INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -9.95 m USD |
| EBIT | -10.31 m USD |
| Net income | -10.31 m USD |
| Diluted EPS – continuing operations | -1.11 USD |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BRAINSTORM CELL THERAPEUTICS INC.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
More stocks
- Trutankless, Inc. (TKLS)
- SUPA Consolidated Inc. (SFCX)
- MASS MEGAWATTS WIND POWER INC (MMMW)
- RESEARCH FRONTIERS INC (REFR)
- VIP Play, Inc. (VIPZ)
- AEON Biopharma, Inc. (AEON)
- STANDARD PREMIUM FINANCE HOLDINGS, INC. (SPFX)
- AVAI BIO, INC. (AVAI)
- Glimpse Group, Inc. (BTLN)
- Wetouch Technology Inc. (WETH)
- Worldwide NFT Inc. (WNFT)
- PREAXIA HEALTH CARE PAYMENT SYSTEMS INC. (PAXH)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.